Innovent and Lilly Announce China Approval for Rituxan Biosimilar
October 12, 2020 at 06:21 AM EDT
Suzhou Innovent Bio and Eli Lilly announced their Rituxan biosimilar was approved in China for lymphoma and leukemia indications. Halpryza® (rituximab injection) is Innovent's fourth mAb approved for China use. It is a recombinant human/murine chimeric monoclonal antibody drug that was co-developed by Innovent and Lilly. The biosimilar is indicated for China patients with diffuse large b cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. More details.... Stock Symbols: (HK: 01801) (NYSE: LLY) Share this with colleagues: // //
